HomeCompareHLSPF vs ABBV

HLSPF vs ABBV: Dividend Comparison 2026

HLSPF yields 1428.57% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HLSPF wins by $450506417.79M in total portfolio value
10 years
HLSPF
HLSPF
● Live price
1428.57%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$450506417.90M
Annual income
$395,979,768,203,621.75
Full HLSPF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HLSPF vs ABBV

📍 HLSPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLSPFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLSPF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLSPF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLSPF
Annual income on $10K today (after 15% tax)
$121,428.57/yr
After 10yr DRIP, annual income (after tax)
$336,582,802,973,078.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HLSPF beats the other by $336,582,802,952,022.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLSPF + ABBV for your $10,000?

HLSPF: 50%ABBV: 50%
100% ABBV50/50100% HLSPF
Portfolio after 10yr
$225253209.00M
Annual income
$197,989,884,114,196.75/yr
Blended yield
87.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HLSPF
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLSPF buys
0
ABBV buys
0
No recent congressional trades found for HLSPF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLSPFABBV
Forward yield1428.57%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$450506417.90M$102.3K
Annual income after 10y$395,979,768,203,621.75$24,771.77
Total dividends collected$446517047.78M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HLSPF vs ABBV ($10,000, DRIP)

YearHLSPF PortfolioHLSPF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$153,557$142,857.14$11,550$430.00+$142.0KHLSPF
2$2,214,468$2,050,162.12$13,472$627.96+$2.20MHLSPF
3$30,000,943$27,631,462.06$15,906$926.08+$29.99MHLSPF
4$381,953,954$349,852,945.12$19,071$1,382.55+$381.93MHLSPF
5$4,571,417,058$4,162,726,327.26$23,302$2,095.81+$4571.39MHLSPF
6$51,453,661,727$46,562,245,474.49$29,150$3,237.93+$51453.63MHLSPF
7$544,851,809,170$489,796,391,122.49$37,536$5,121.41+$544851.77MHLSPF
8$5,430,224,629,042$4,847,233,193,230.08$50,079$8,338.38+$5430224.58MHLSPF
9$50,959,485,695,016$45,149,145,341,941.08$69,753$14,065.80+$50959485.63MHLSPF
10$450,506,417,897,289$395,979,768,203,621.75$102,337$24,771.77+$450506417.79MHLSPF

HLSPF vs ABBV: Complete Analysis 2026

HLSPFStock

Heliospectra AB (publ) provides light control systems and related services for greenhouse and controlled plant growth environments worldwide. It offers MITRA, a modular cooling solution for indoor and greenhouse; ELIXIA, an essential tool for greenhouse or indoor operation; and DYNA, a flexible LED grow light. The company also provides helioCORE, a light control system that offers crop production, as well as enables clients to forecast production, predict yield, and maximize growth; and helioCARE, which provides light planning, on site, trials, and cultivation training services. Heliospectra AB (publ) was incorporated in 2005 and is based in Gothenburg, Sweden.

Full HLSPF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HLSPF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLSPF vs SCHDHLSPF vs JEPIHLSPF vs OHLSPF vs KOHLSPF vs MAINHLSPF vs JNJHLSPF vs MRKHLSPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.